Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII

Blood

Volumn 127, Issue 5, 2016, Pages 565-571

  Marcos Contreras, Oscar A ^a   Smith, Shannon M ^a   Bellinger, Dwight A ^b   Raymer, Robin A ^b   Merricks, Elizabeth ^b   Faella, Armida ^a   Pavani, Giulia ^a   Zhou, Shangzhen ^a   Nichols, Timothy C ^b   High, Katherine A ^a   Margaritis, Paris ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; D DIMER; ENZYME PRECURSOR; FIBRINOGEN; IMMUNOGLOBULIN G2; PARVOVIRUS VECTOR; PREPRO-FACTOR VII; PROTEIN PRECURSOR;

ADENO ASSOCIATED VIRUS 8; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BLOOD CHEMISTRY; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; DOG; GENE THERAPY; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; THROMBOCYTE COUNT; TRANSGENE; WESTERN BLOTTING; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; FACTOR VII DEFICIENCY; GENE EXPRESSION; GENE VECTOR; GENETICS; HEK293 CELL LINE; POINT MUTATION; THERAPEUTIC USE;

ADENOVIRIDAE; ANIMALS; DOGS; FACTOR VII; FACTOR VII DEFICIENCY; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; POINT MUTATION; PROTEIN PRECURSORS; TRANSGENES;

EID: 84958212770     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-671420     Document Type: Article

References (38)

1. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004; 104(5):1243-1252.
2. Perry DJ. Factor VII deficiency. Br J Haematol. 2002;118(3):689-700.
3. Bernardi F, Dolce A, Pinotti M, et al; International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost. 2009;7(5):774-779.
4. Siboni SM, Biguzzi E, Mistretta C, Garagiola I, Peyvandi F. Long-term prophylaxis in severe factor VII deficiency. Haemophilia. 2015;21(6): 812-819.
5. Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost. 2009;35(4):400-406.
6. Napolitano M, Giansily-Blaizot M, Dolce A, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica. 2013;98(4):538-544.
7. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014; 371(21):1994-2004.
8. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vectormediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
9. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost. 2000;26(4):385-392.
10. Binny C, McIntosh J, Della Peruta M, et al. AAVmediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood. 2012;119(4):957-966.
11. Benlakhal F, Mura T, Schved JF, Giansily-Blaizot M; French Study Group of Factor VII Deficiency. A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost. 2011;9(6):1149-1156.
12. Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost. 2000;26(4):401-406.
13. Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia. 2006;12(1):19-27.
14. Mariani G, Lapecorella M, Dolce A. Steps towards an effective treatment strategy in congenital factor VII deficiency. Semin Hematol. 2006;43(1, suppl 1): S42-S47.
15. Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood. 2009;113(16):3682-3689.
16. Nichols TC, Whitford MH, Arruda VR, Stedman HH, Kay MA, High KA. Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev. 2015;26(1):5-14.
17. Callan MB, Aljamali MN, Margaritis P, et al. A novel missense mutation responsible for factor VII deficiency in research Beagle colonies. J Thromb Haemost. 2006;4(12):2616-2622.
18. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated factor VII. J Clin Invest. 2004;113(7):1025-1031.
19. Sabatino DE, Lange AM, Altynova ES, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther. 2011;19(3): 442-449.
20. Knudsen T, Kjelgaard-Hansen M, Tranholm M, et al. Canine specific ELISA for coagulation factor VII. Vet J. 2011;190(3):352-358.
21. Margaritis P, Roy E, Faella A, et al. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo. Blood. 2011;117(15):3974-3982.
22. Dewhurst E, Cue S, Crawford E, Papasouliotis K. A retrospective study of canine D-dimer concentrations measured using an immunometric "Point-of-Care" test. J Small Anim Pract. 2008; 49(7):344-348.
23. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89(4): 601-609.
24. Nelson OL. Use of the D-dimer assay for diagnosing thromboembolic disease in the dog. J Am Anim Hosp Assoc. 2005;41(3):145-149.
25. Monahan PE. Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb Haemost. 2015;13(suppl 1):S151-S160.
26. Rosen ED, Xu H, Liang Z, Martin JA, Suckow M, Castellino FJ. Generation of genetically-altered mice producing very low levels of coagulation factorVII. Thromb Haemost. 2005;94(3):493-497.
27. Petersen LC, Nørby PL, Branner S, et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res. 2005;116(1):75-85.
28. Clark CA, Vatsyayan R, Hedner U, Esmon CT, Pendurthi UR, Rao LV. Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa. J Thromb Haemost. 2012;10(11):2383-2391.
29. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
30. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700-710.
31. Girolami A, Sambado L, Bonamigo E, Ferrari S, Lombardi AM. Pathogenetic role of factor VII deficiency and thrombosis in cross-reactive material positive patients. Lab Hematol. 2013; 19(4):17-21.
32. Ingerslev J, Christiansen K, Sørensen B; International Registry on Factor VII Deficiency (IRF7) Steering Committee. Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response. J Thromb Haemost. 2005;3(4):799-800.
33. Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. Haemophilia. 2015;21(5):686-692.
34. Tokgoz H, Caliskan U, Lavigne-Lissalde G, Giansily-Blaizot M. Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII. Haemophilia. 2012;18(1): e25-e27.
35. Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. 2010;116(26):5842-5848.
36. Chuah MK, Petrus I, De Bleser P, et al. Liverspecific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol Ther. 2014;22(9):1605-1613.
37. Pierce EA, Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med. 2015;5(9):a017285.
38. Scott LJ. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs. 2015;75(2):175-182.